Medpage Today on MSN2d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback